GlobeNewswire: BIOPHYTIS SA Contains the last 10 of 90 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:12:44ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/10/06/2309918/0/en/Biophytis-to-Restate-Previously-Issued-Financial-Statements.html?f=22&fvtc=4&fvtv=29988Biophytis to Restate Previously Issued Financial Statements 2021-10-06T21:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced that the Company’s previously issued audited consolidated financial statements for the fiscal years ended December 31, 2019 and 2020 and unaudited consolidated financial statements for the six month periods ended June 30, 2021 and 2020 will be restated to correct the Company’s accounting treatment of its convertible notes.]]>https://www.globenewswire.com/news-release/2021/10/06/2309269/0/en/Biophytis-to-Host-Virtual-KOL-Event-on-Sarconeos-BIO101-on-its-Lead-Projects-in-COVID-19-and-Sarcopenia.html?f=22&fvtc=4&fvtv=29988Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia2021-10-06T06:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia.]]>https://www.globenewswire.com/news-release/2021/10/04/2308337/0/en/Biophytis-Announces-the-Drawing-of-2-New-Tranches-of-ORNANE-Under-the-2020-Atlas-Contract-for-6-Million.html?f=22&fvtc=4&fvtv=29988Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million2021-10-04T21:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the issuance of 240 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €6 million under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York (United States) for €24 million (the "2020 Atlas Contract").]]>https://www.globenewswire.com/news-release/2021/10/04/2307540/0/en/Biophytis-Announces-Promising-Full-Results-From-the-SARA-INT-Phase-2b-Trial-of-Sarconeos-BIO101-in-Sarcopenia-at-the-11th-Annual-International-Conference-on-Frailty-and-Sarcopenia-.html?f=22&fvtc=4&fvtv=29988Biophytis Announces Promising Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 20212021-10-04T06:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the full results from the SARA-INT Phase 2 trial of Sarconeos (BIO101) in Sarcopenia that have been presented at the International Conference on Frailty and Sarcopenia Research (ICFSR) on September, 30th. ICFSR is the key international scientific event on Frailty and Sarcopenia and is attended by leading researchers, physicians and Biotech/Pharma in this field.]]>Effect of Sarconeos (BIO101) on the 400 MWT gait speed in the FAS and PP populationsFigure 1Effect of Sarconeos (BIO101) on the 400MWT gait speed in sub-population with higher risk of mobility disability (chair stand subscore ≤2)Figure 2Adverse Events, Serious Adverse Events and Treatment Emergent Adverse Events in the Placebo, 175 mg bid and 350 mg bid groups in the SARA-INT studyFigure 3https://www.globenewswire.com/news-release/2021/09/29/2305032/0/en/Biophytis-to-Present-Full-Results-From-the-SARA-INT-Phase-2b-Trial-of-Sarconeos-BIO101-in-Sarcopenia-at-the-11th-Annual-International-Conference-on-Frailty-and-Sarcopenia-Research-.html?f=22&fvtc=4&fvtv=29988Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 20212021-09-29T06:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will present full results from the SARA-INT Phase 2 trial of Sarconeos (BIO101) in Sarcopenia at the International Congress on Frailty and Sarcopenia Research (ICFSR) to be held virtually from September 29 to October 02, 2021.]]>https://www.globenewswire.com/news-release/2021/09/17/2298856/0/en/Biophytis-Reports-H1-2021-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=29988Biophytis Reports H1 2021 Financial Results and Provides Business Update2021-09-17T06:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today publishes its interim financial report for the first half of 2021 and provides updates on key operational developments and financing transactions.]]>https://www.globenewswire.com/news-release/2021/09/15/2297160/0/en/Biophytis-Announces-DMC-Second-Interim-Analysis-Efficacy-Results-in-the-Promising-Zone-Allowing-Continuation-of-Phase-2-3-COVA-Study-With-Sarconeos-BIO101-in-COVID-19.html?f=22&fvtc=4&fvtv=29988Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-192021-09-15T06:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the recommendation by the Data Monitoring Committee (DMC) to continue the Phase 2-3 COVA study without any modification of the protocol, after the interim efficacy data were found in the promising zone in the Interim Analysis 2 based on 155 COVID-19 patients hospitalized with respiratory failure. This recommendation completes previous safety evaluation performed by DMC last August (Press Release August, 16th) that confirmed the good safety profile of Sarconeos (BIO101).]]>https://www.globenewswire.com/news-release/2021/09/14/2296286/0/en/Biophytis-to-Attend-Key-Upcoming-Investor-Events-and-Industry-Conferences.html?f=22&fvtc=4&fvtv=29988Biophytis to Attend Key Upcoming Investor Events and Industry Conferences2021-09-14T06:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces its management will participate and meet with investors at the following upcoming events and conferences:]]>https://www.globenewswire.com/news-release/2021/09/09/2293937/0/en/Biophytis-Leadership-is-Reinforced-With-New-Chief-Medical-Officer-Appointment.html?f=22&fvtc=4&fvtv=29988Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment2021-09-09T06:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, today announces the appointment of Rob van Maanen MD MBA as Chief Medical Officer, member of the Executive Committee.]]>https://www.globenewswire.com/news-release/2021/08/16/2280811/0/en/Biophytis-Receives-Favorable-Recommendation-From-Data-Monitoring-Committee-DMC-Based-on-Safety-Analysis-of-Sarconeos-BIO101-to-Continue-Patient-Recruitment-in-the-COVA-Study-in-COV.html?f=22&fvtc=4&fvtv=29988Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-192021-08-16T06:00:00Z<![CDATA[PARIS and CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the recommendation by the Data Monitoring Committee (DMC) to continue patient recruitment into part 2 of the COVA study with the protocol unmodified after review of safety data.]]>